International Journal of Clinical Practice 2006; 60(9): 1138-45, Palmer AJ, Nicklasson L, Cobden D, Roze S. Improving life expectancy and decreasing the incidence of complications associated with type 2 diabetes: a modelling study of HbA1c targets.
Palmer AJ, Current Medical Research and Opinion 2006; 22(11): 2095-100, Tucker DM, Ray JA, Roze S, Annemans L, Lapuerta P, Chen R, Gabriel S, Carita P, Rodby RA, de ZD, Parving HH, Laville M. A French cost-consequence analysis of the renoprotective benefits of irbesartan in patients with type 2 diabetes and hypertension.
Palmer AJ, Roze S, Swiss Medical Weekly 2006; 136(21): 346-52, Ray JA, Frei A, Burnier M, Hess B, Spinas GA, Brandle M. Health economic implications of irbesartan plus conventional antihypertensive medications versus conventional blood pressure control alone in patients with type 2 diabetes, hypertension, and renal disease in Switzerland.
Tucker DM, Palmer AJ, Current Medical Research and Opinion 2006; 22(3): 346-52, Roze S, Ray JA. Counting the costs of overweight and obesity: modeling clinical and cost outcomes.
Advances in Therapy 2006; 23(2): 191-207, Palmer AJ, Erny-Albrecht KM, Ray JA, Cobden D, Foos V, Lurati FM, Roze S. Cost-effectiveness of basal insulin from a US health system perspective: comparative analyses of detemir, glargine, and NPH.
Roze S, Current Medical Research and Opinion 2006; 22(7): 1415-24, Evers T, Palmer AJ. Acarbose in addition to existing treatments in patients with type 2 diabetes: health economic analysis in a German setting.
Palmer AJ, Chen R, Diabetes and Metabolism 2006; 32(1): 69-76, Roze S, Bregman B, Mehin N, Gabriel S. Cost-consequence analysis in a French setting of screening and optimal treatment of nephropathy in hypertensive patients with type 2 diabetes.
Palmer AJ, Roze S, Rodby RA, Deutsche Medizinische Wochenschrift 2006; 131(31): 1721-6, Ritz E, Lehnert H. Clinical and health economic implications of early treatment with irbesartan of patients with type 2 diabetes mellitus, hypertension and nephropathy.